

Jakub GoÅ,Äb

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3750740/publications.pdf>

Version: 2024-02-01

164
papers

13,722
citations

76326

40
h-index

21540

114
g-index

169
all docs

169
docs citations

169
times ranked

23750
citing authors

#	ARTICLE	IF	CITATIONS
1	Photodynamic therapy of cancer: An update. <i>Ca-A Cancer Journal for Clinicians</i> , 2011, 61, 250-281.	329.8	3,902
2	Guidelines for the use and interpretation of assays for monitoring autophagy. <i>Autophagy</i> , 2012, 8, 445-544.	9.1	3,122
3	A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. <i>EMBO Journal</i> , 2012, 31, 1062-1079.	7.8	641
4	Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death. <i>Frontiers in Immunology</i> , 2015, 6, 588.	4.8	317
5	Immunogenic cell death, DAMPs and anticancer therapeutics: An emerging amalgamation. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2010, 1805, 53-71.	7.4	292
6	Photodynamic therapy: illuminating the road from cell death towards anti-tumour immunity. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2010, 15, 1050-1071.	4.9	253
7	Myeloid Cell-Derived Arginase in Cancer Immune Response. <i>Frontiers in Immunology</i> , 2020, 11, 938.	4.8	249
8	Direct tumor damage mechanisms of photodynamic therapy.. <i>Acta Biochimica Polonica</i> , 2005, 52, 339-352.	0.5	222
9	Aminolevulinic Acid (ALA) as a Prodrug in Photodynamic Therapy of Cancer. <i>Molecules</i> , 2011, 16, 4140-4164.	3.8	198
10	Small extracellular vesicles containing arginase-1 suppress T-cell responses and promote tumor growth in ovarian carcinoma. <i>Nature Communications</i> , 2019, 10, 3000.	12.8	194
11	Danger signalling during cancer cell death: origins, plasticity and regulation. <i>Cell Death and Differentiation</i> , 2014, 21, 26-38.	11.2	187
12	Natural mechanisms protecting against cancer. <i>Immunology Letters</i> , 2003, 90, 103-122.	2.5	181
13	Heme oxygenase-1 protects tumor cells against photodynamic therapy-mediated cytotoxicity. <i>Oncogene</i> , 2006, 25, 3365-3374.	5.9	163
14	Effective Photoimmunotherapy of Murine Colon Carcinoma Induced by the Combination of Photodynamic Therapy and Dendritic Cells. <i>Clinical Cancer Research</i> , 2004, 10, 4498-4508.	7.0	142
15	Induction of heme-oxygenase 1 requires the p38MAPK and PI3K pathways and suppresses apoptotic cell death following hypericin-mediated photodynamic therapy. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2007, 12, 731-741.	4.9	119
16	Statins Impair Antitumor Effects of Rituximab by Inducing Conformational Changes of CD20. <i>PLoS Medicine</i> , 2008, 5, e64.	8.4	115
17	Cardiotoxicity of the Anticancer Therapeutic Agent Bortezomib. <i>American Journal of Pathology</i> , 2010, 176, 2658-2668.	3.8	115
18	Antitumor Effects of Photodynamic Therapy Are Potentiated by 2-Methoxyestradiol. <i>Journal of Biological Chemistry</i> , 2003, 278, 407-414.	3.4	113

#	ARTICLE	IF	CITATIONS
19	Interleukin 15 as a promising candidate for tumor immunotherapy. <i>Cytokine and Growth Factor Reviews</i> , 2011, 22, 99-108.	7.2	102
20	Proteasome Inhibition Potentiates Antitumor Effects of Photodynamic Therapy in Mice through Induction of Endoplasmic Reticulum Stress and Unfolded Protein Response. <i>Cancer Research</i> , 2009, 69, 4235-4243.	0.9	96
21	Antitumor Immunity Triggered by Melphalan Is Potentiated by Melanoma Cell Surface-Associated Calreticulin. <i>Cancer Research</i> , 2015, 75, 1603-1614.	0.9	86
22	The influence of photodynamic therapy on the immune response. <i>Photodiagnosis and Photodynamic Therapy</i> , 2005, 2, 283-298.	2.6	83
23	PDT-induced inflammatory and host responses. <i>Photochemical and Photobiological Sciences</i> , 2011, 10, 653-663.	2.9	76
24	Potential antitumor effects of statins (Review). <i>International Journal of Oncology</i> , 2003, 23, 1055-69.	3.3	74
25	Antitumor effects of the combination immunotherapy with interleukin-12 and tumor necrosis factor $\hat{\pm}$ in mice. <i>Cancer Immunology, Immunotherapy</i> , 1997, 45, 100-108.	4.2	63
26	Direct tumor damage mechanisms of photodynamic therapy. <i>Acta Biochimica Polonica</i> , 2005, 52, 339-52.	0.5	63
27	Exploring the Anti-Cancer Activity of Novel Thiosemicarbazones Generated through the Combination of Retro-Fragments: Dissection of Critical Structure-Activity Relationships. <i>PLoS ONE</i> , 2014, 9, e110291.	2.5	61
28	Zinc protoporphyrin IX, a heme oxygenase-1 inhibitor, demonstrates potent antitumor effects but is unable to potentiate antitumor effects of chemotherapeutics in mice. <i>BMC Cancer</i> , 2008, 8, 197.	2.6	59
29	INTERLEUKIN 18-INTERFERON $\hat{\beta}$ INDUCING FACTOR-A NOVEL PLAYER IN TUMOUR IMMUNOTHERAPY?. <i>Cytokine</i> , 2000, 12, 332-338.	3.2	58
30	Potential antitumor effects of statins (Review). <i>International Journal of Oncology</i> , 2003, 23, 1055.	3.3	56
31	5-Aza-2-deoxycytidine potentiates antitumour immune response induced by photodynamic therapy. <i>European Journal of Cancer</i> , 2014, 50, 1370-1381.	2.8	56
32	B-cell receptor pathway inhibitors affect CD20 levels and impair antitumor activity of anti-CD20 monoclonal antibodies. <i>Leukemia</i> , 2014, 28, 1163-1167.	7.2	54
33	GRP78-targeting subtilase cytotoxin sensitizes cancer cells to photodynamic therapy. <i>Cell Death and Disease</i> , 2013, 4, e741-e741.	6.3	52
34	Advances in Ex Situ Tissue Optical Clearing. <i>Laser and Photonics Reviews</i> , 2019, 13, 1800292.	8.7	52
35	Targeting peroxiredoxin 1 impairs growth of breast cancer cells and potently sensitises these cells to prooxidant agents. <i>British Journal of Cancer</i> , 2018, 119, 873-884.	6.4	49
36	Dimeric peroxiredoxins are druggable targets in human Burkitt lymphoma. <i>Oncotarget</i> , 2016, 7, 1717-1731.	1.8	48

#	ARTICLE	IF	CITATIONS
37	Inhibition of cyclooxygenase-2 indirectly potentiates antitumor effects of photodynamic therapy in mice. <i>Clinical Cancer Research</i> , 2003, 9, 5417-22.	7.0	46
38	The possible role of factor H in colon cancer resistance to complement attack. <i>International Journal of Cancer</i> , 2008, 122, 2030-2037.	5.1	44
39	Studies toward Novel Peptidomimetic Inhibitors of Thioredoxinâ€“Thioredoxin Reductase System. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 55-67.	6.4	44
40	Combined Effect of Proteasome and Calpain Inhibition on Cisplatin-Resistant Human Melanoma Cells. <i>Cancer Research</i> , 2006, 66, 7598-7605.	0.9	43
41	Cyclosporine A and its non-immunosuppressive derivative NIM811 induce apoptosis of malignant melanoma cells in vitro and in vivo studies. <i>International Journal of Cancer</i> , 2005, 117, 59-67.	5.1	40
42	Bortezomib modulates surface CD20 in B-cell malignancies and affects rituximab-mediated complement-dependent cytotoxicity. <i>Blood</i> , 2010, 115, 3745-3755.	1.4	40
43	Molecular mechanisms of the antitumor effects of anti-CD20 antibodies. <i>Frontiers in Bioscience - Landmark</i> , 2011, 16, 277.	3.0	40
44	HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies. <i>Blood</i> , 2017, 130, 1628-1638.	1.4	40
45	Effective chemo-immunotherapy of L1210 leukemia in vivo using interleukin-12 combined with doxorubicin but not with cyclophosphamide, paclitaxel or cisplatin. <i>International Journal of Cancer</i> , 1998, 77, 720-727.	5.1	39
46	Inhibition of lymphangiogenesis impairs antitumour effects of photodynamic therapy and checkpoint inhibitors in mice. <i>European Journal of Cancer</i> , 2017, 83, 19-27.	2.8	39
47	Studies of the Synthesis of All Stereoisomers of MG-132 Proteasome Inhibitors in the Tumor Targeting Approach. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 1509-1518.	6.4	38
48	Statins can modulate effectiveness of antitumor therapeutic modalities. <i>Medicinal Research Reviews</i> , 2010, 30, 102-135.	10.5	37
49	Statins Impair Glucose Uptake in Tumor Cells. <i>Neoplasia</i> , 2012, 14, 311-323.	5.3	37
50	Statins impair glucose uptake in human cells. <i>BMJ Open Diabetes Research and Care</i> , 2014, 2, e000017.	2.8	37
51	The role of CD71+ erythroid cells in the regulation of the immune response. , 2021, 228, 107927.		37
52	Adenanthin targets proteins involved in the regulation of disulphide bonds. <i>Biochemical Pharmacology</i> , 2014, 89, 210-216.	4.4	36
53	Inhibition of autophagy sensitizes cancer cells to Photofrin-based photodynamic therapy. <i>BMC Cancer</i> , 2018, 18, 210.	2.6	36
54	Potential of antitumor effects of tumor necrosis factor $\hat{\pm}$ and interferon $\hat{\beta}$ by macrophage-colony-stimulating factor in a Mmb16 melanoma model in mice. <i>Cancer Immunology, Immunotherapy</i> , 1995, 40, 315-321.	4.2	35

#	ARTICLE	IF	CITATIONS
55	CpG Immunostimulatory Oligodeoxynucleotide 1826 Enhances Antitumor Effect of Interleukin 12 Gene-Modified Tumor Vaccine in a Melanoma Model in Mice. <i>Clinical Cancer Research</i> , 2004, 10, 4165-4175.	7.0	35
56	Statins potentiate cytostatic/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitro. <i>Cancer Letters</i> , 2010, 288, 57-67.	7.2	34
57	Immunoglobulin expression and the humoral immune response is regulated by the non-canonical poly(A) polymerase TENT5C. <i>Nature Communications</i> , 2020, 11, 2032.	12.8	34
58	Role of the ubiquitinâ€“proteasome pathway in the diagnosis of human diseases. <i>Clinica Chimica Acta</i> , 2004, 340, 27-40.	1.1	33
59	Direct stimulation of macrophages by IL-12 and IL-18 â€” a bridge too far?. <i>Immunology Letters</i> , 2000, 72, 153-157.	2.5	31
60	The dual role of tumor lymphatic vessels in dissemination of metastases and immune response development. <i>Oncolmmunology</i> , 2016, 5, e1182278.	4.6	31
61	Interleukin 12-based immunotherapy improves the antitumor effectiveness of a low-dose 5-Aza-2'-deoxycytidine treatment in L1210 leukemia and B16F10 melanoma models in mice. <i>Clinical Cancer Research</i> , 2003, 9, 3124-33.	7.0	31
62	Iron Chelators in Photodynamic Therapy Revisited: Synergistic Effect by Novel Highly Active Thiosemicarbazones. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 336-339.	2.8	30
63	Inhibition of arginase modulates T-cell response in the tumor microenvironment of lung carcinoma. <i>Oncolmmunology</i> , 2021, 10, 1956143.	4.6	30
64	Optimization and regeneration kinetics of lymphatic-specific photodynamic therapy in the mouse dermis. <i>Angiogenesis</i> , 2014, 17, 347-357.	7.2	29
65	Inhibition of thioredoxin-dependent H2O2 removal sensitizes malignant B-cells to pharmacological ascorbate. <i>Redox Biology</i> , 2019, 21, 101062.	9.0	29
66	Tumor Immune Evasion Induced by Dysregulation of Erythroid Progenitor Cells Development. <i>Cancers</i> , 2021, 13, 870.	3.7	28
67	Potential of the anti-tumor effect of actinomycin D by tumor necrosis factor Î± in mice: Correlation between in vitro and in vivo results. , 1996, 66, 374-379.		27
68	Discovery and Pharmacokinetics of Sulfamides and Guanidines as Potent Human Arginase 1 Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 433-438.	2.8	27
69	SK053 triggers tumor cells apoptosis by oxidative stress-mediated endoplasmic reticulum stress. <i>Biochemical Pharmacology</i> , 2015, 93, 418-427.	4.4	26
70	MEK Inhibition Sensitizes Precursor B-Cell Acute Lymphoblastic Leukemia (B-ALL) Cells to Dexamethasone through Modulation of mTOR Activity and Stimulation of Autophagy. <i>PLoS ONE</i> , 2016, 11, e0155893.	2.5	26
71	Erythropoietin restores the antitumor effectiveness of photodynamic therapy in mice with chemotherapy-induced anemia. <i>Clinical Cancer Research</i> , 2002, 8, 1265-70.	7.0	26
72	Antitumor effects of the combination therapy with TNF-Î± geneâ€“modified tumor cells and interleukin 12 in a melanoma model in mice. <i>Cancer Gene Therapy</i> , 2000, 7, 1581-1590.	4.6	25

#	ARTICLE	IF	CITATIONS
73	Targeting Epigenetic Processes in Photodynamic Therapy-Induced Anticancer Immunity. <i>Frontiers in Oncology</i> , 2015, 5, 176.	2.8	25
74	Targeting the thioredoxin system as a novel strategy against Bâ€cell acute lymphoblastic leukemia. <i>Molecular Oncology</i> , 2019, 13, 1180-1195.	4.6	24
75	FOXO1 promotes resistance of non-Hodgkin lymphomas to anti-CD20-based therapy. <i>Oncolmunology</i> , 2018, 7, e1423183.	4.6	23
76	Targeting Acidic Mammalian chitinase Is Effective in Animal Model of Asthma. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 695-710.	6.4	23
77	Development of Dual Chitinase Inhibitors as Potential New Treatment for Respiratory System Diseases. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 7126-7145.	6.4	22
78	Apoptosis induced in L1210 leukaemia cells by an inhibitor of the chymotrypsin-like activity of the proteasome. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 1997, 2, 455-462.	4.9	21
79	Antitumor Activity of TLR7 Is Potentiated by CD200R Antibody Leading to Changes in the Tumor Microenvironment. <i>Cancer Immunology Research</i> , 2018, 6, 930-940.	3.4	21
80	Prospects for p53-based cancer therapy.. <i>Acta Biochimica Polonica</i> , 2005, 52, 321-328.	0.5	21
81	Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies. <i>Cancer Research</i> , 2021, 81, 6029-6043.	0.9	20
82	Prenyltransferases Regulate CD20 Protein Levels and Influence Anti-CD20 Monoclonal Antibody-mediated Activation of Complement-dependent Cytotoxicity. <i>Journal of Biological Chemistry</i> , 2012, 287, 31983-31993.	3.4	19
83	Upregulation of MLK4 promotes migratory and invasive potential of breast cancer cells. <i>Oncogene</i> , 2019, 38, 2860-2875.	5.9	19
84	Discovery of OATD-01, a First-in-Class Chitinase Inhibitor as Potential New Therapeutics for Idiopathic Pulmonary Fibrosis. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 15527-15540.	6.4	18
85	Cerivastatin demonstrates enhanced antitumor activity against human breast cancer cell lines when used in combination with doxorubicin or cisplatin. <i>International Journal of Oncology</i> , 2004, 24, 1149.	3.3	17
86	Biodistribution and Efficacy Studies of the Proteasome Inhibitor BSc2118 in a Mouse Melanoma Model. <i>Translational Oncology</i> , 2014, 7, 570-579.	3.7	17
87	Photochemical delivery of bleomycin induces T-cell activation of importance for curative effect and systemic anti-tumor immunity. <i>Journal of Controlled Release</i> , 2017, 268, 120-127.	9.9	17
88	Immunomodulation by anticancer chemotherapy: More is not always better (Review). <i>International Journal of Oncology</i> , 2001, 18, 417-24.	3.3	16
89	Potentiating antitumor effects of a combination therapy with lovastatin and butyrate in the Lewis lung carcinoma model in mice. <i>International Journal of Cancer</i> , 2002, 97, 746-750.	5.1	16
90	Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies. <i>MAbs</i> , 2014, 6, 1300-1313.	5.2	16

#	ARTICLE	IF	CITATIONS
91	Adenanthin, a new inhibitor of thiolâ€dependent antioxidant enzymes, impairs the effector functions of human natural killer cells. <i>Immunology</i> , 2015, 146, 173-183.	4.4	16
92	Cholesterol restricts lymphotoxin Î² receptor-triggered NF-Î²B signaling. <i>Cell Communication and Signaling</i> , 2019, 17, 171.	6.5	16
93	Bone marrow is the preferred site of memory CD4+ T cell proliferation during recovery from sepsis. <i>JCI Insight</i> , 2020, 5, .	5.0	16
94	Review Cancer stem cells in haematological malignancies. <i>Wspolczesna Onkologia</i> , 2015, 1A, 1-6.	1.4	15
95	Erythropoietin Prevents the Development of Interleukin-12â€Induced Anemia and Thrombocytopenia But Does Not Decrease Its Antitumor Activity in Mice. <i>Blood</i> , 1998, 91, 4387-4388.	1.4	14
96	Topical ALAâ€PDT modifies neutrophilsâ€™ chemiluminescence, lymphocytesâ€™ interleukin-1beta secretion and serum level of transforming growth factor beta1 in patients with nonmelanoma skin malignancies. <i>Photodiagnosis and Photodynamic Therapy</i> , 2005, 2, 65-72.	2.6	13
97	Dissection of CD20 regulation in lymphoma using RNAi. <i>Leukemia</i> , 2016, 30, 2409-2412.	7.2	13
98	Discovery of selective, orally bioavailable inhibitor of mouse chitotriosidase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 310-314.	2.2	13
99	Inhibition of IDO leads to IL-6-dependent systemic inflammation in mice when combined with photodynamic therapy. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1101-1112.	4.2	13
100	Investigation of cell death mechanisms in human lymphatic endothelial cells undergoing photodynamic therapy. <i>Photodiagnosis and Photodynamic Therapy</i> , 2016, 14, 57-65.	2.6	12
101	Potent but transient immunosuppression of T-cells is a general feature of CD71+ erythroid cells. <i>Communications Biology</i> , 2021, 4, 1384.	4.4	12
102	Drug delivery technologies and immunological aspects of photodynamic therapy. <i>Photochemical and Photobiological Sciences</i> , 2011, 10, 647-648.	2.9	11
103	Lovastatin potentiates antitumor effects of saquinavir against human lymphoma cells. <i>Oncology Reports</i> , 2004, 12, 1371-5.	2.6	11
104	The Influence of Time of Day of Vaccination with BNT162b2 on the Adverse Drug Reactions and Efficacy of Humoral Response against SARS-CoV-2 in an Observational Study of Young Adults. <i>Vaccines</i> , 2022, 10, 443.	4.4	11
105	Discussion on 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. <i>Gastroenterology</i> , 2002, 123, 1747.	1.3	10
106	Epigenetic remodeling combined with photodynamic therapy elicits anticancer immune responses. <i>Oncolmmunology</i> , 2014, 3, e28837.	4.6	10
107	A New Inhibitor of Tubulin Polymerization Kills Multiple Cancer Cell Types and Reveals p21-Mediated Mechanism Determining Cell Death after Mitotic Catastrophe. <i>Cancers</i> , 2020, 12, 2161.	3.7	10
108	Systematic Evaluation of Chemically Distinct Tissue Optical Clearing Techniques in Murine Lymph Nodes. <i>Journal of Immunology</i> , 2020, 204, 1395-1407.	0.8	10

#	ARTICLE	IF	CITATIONS
109	Inhibition of CHIT1 as a novel therapeutic approach in idiopathic pulmonary fibrosis. <i>European Journal of Pharmacology</i> , 2022, 919, 174792.	3.5	10
110	The potentiated antileukemic effects of doxorubicin and interleukin-12 combination are not dependent on nitric oxide production. <i>Cancer Letters</i> , 1999, 147, 67-75.	7.2	9
111	Extracellular vesicles released by ovarian carcinoma contain arginase 1 that mitigates antitumor immune response. <i>Oncolimmunology</i> , 2019, 8, e1655370.	4.6	9
112	The pro-tumor effect of CD200 expression is not mimicked by agonistic CD200R antibodies. <i>PLoS ONE</i> , 2019, 14, e0210796.	2.5	9
113	Benzoxazepine-Derived Selective, Orally Bioavailable Inhibitor of Human Acidic Mammalian Chitinase. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 1228-1235.	2.8	9
114	Potent, p53-independent induction of NOXA sensitizes MLL-rearranged B-cell acute lymphoblastic leukemia cells to venetoclax. <i>Oncogene</i> , 2022, 41, 1600-1609.	5.9	9
115	Application of a proteomic approach to identify proteins associated with primary graft non-function after liver transplantation. <i>International Journal of Molecular Medicine</i> , 2012, 30, 755-764.	4.0	8
116	Inhibition of protein disulfide isomerase induces differentiation of acute myeloid leukemia cells. <i>Haematologica</i> , 2018, 103, 1843-1852.	3.5	8
117	Potentiated antitumor effects of the combination treatment with statins and pamidronate in vitro and in vivo. <i>International Journal of Oncology</i> , 2007, 30, 1413-25.	3.3	8
118	Berberine, a natural cholesterol reducing product, exerts antitumor cytostatic/cytotoxic effects independently from the mevalonate pathway. <i>Oncology Reports</i> , 2006, 16, 1273.	2.6	7
119	Photodynamic therapy-driven induction of suicide cytosine deaminase gene. <i>Cancer Letters</i> , 2010, 290, 216-222.	7.2	7
120	Antitumor effects of the combination of cholesterol reducing drugs. <i>Oncology Reports</i> , 2011, 26, 169-76.	2.6	7
121	A Combination of Retinoic Acid and Proteasome Inhibitors for the Treatment of Leukemias Is Potentially Dangerous. <i>Blood</i> , 1999, 94, 1827-1828.	1.4	6
122	Augmented antitumour effects of combination therapy with TNP-470 and chemoimmunotherapy in mice. <i>Journal of Cancer Research and Clinical Oncology</i> , 2002, 128, 433-442.	2.5	6
123	Potentiated antitumor effects of the combination treatment with statins and pamidronate in vitro and in vivo. <i>International Journal of Oncology</i> , 2007, , .	3.3	6
124	Selection of an optimal promoter for gene transfer in normal B cells. <i>Molecular Medicine Reports</i> , 2017, 16, 3041-3048.	2.4	6
125	Increased local vascular endothelial growth factor expression associated with antitumor activity of proteasome inhibitor. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2004, 9, 193-204.	4.9	5
126	Stimulation of TNF-Î± production by 2-(1-adamantylamino)-6-methylpyridine (AdAMP) - a novel immunomodulator with potential application in tumour immunotherapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2002, 50, 213-222.	2.3	4

#	ARTICLE	IF	CITATIONS
127	AAF-cmk sensitizes tumor cells to trail-mediated apoptosis. <i>Leukemia Research</i> , 2004, 28, 53-61.	0.8	4
128	Proteolytic pathways involved in modulation of CD20 levels. <i>Autophagy</i> , 2010, 6, 810-812.	9.1	4
129	Sorafenib improves rituximab and ofatumumab efficacy by decreasing the expression of complement regulatory proteins. <i>Blood Cancer Journal</i> , 2015, 5, e300-e300.	6.2	4
130	Melanoma targeting with the loco-regional chemotherapeutic, Melphalan: From cell death to immunotherapeutic efficacy. <i>Oncolmmunology</i> , 2015, 4, e1054600.	4.6	4
131	Low dose of GRP78-targeting subtilase cytotoxin improves the efficacy of photodynamic therapy in vivo. <i>Oncology Reports</i> , 2016, 35, 3151-3158.	2.6	4
132	Demethylating agent 5-aza-2'-deoxycytidine enhances expression of TNFRI and promotes TNF-mediated apoptosis in vitro and in vivo. <i>Oncology Reports</i> , 0, , .	2.6	4
133	A single injection of immature dendritic cells is able to induce antitumour response against a murine colon adenocarcinoma with a low apoptotic index. <i>Oncology Reports</i> , 2002, 9, 991.	2.6	3
134	Erythropoietin reduces cisplatin-induced neurotoxicity without impairment of cytotoxic effects against tumor cells. <i>International Journal of Oncology</i> , 2007, 31, 1547-52.	3.3	3
135	Pentoxifylline inhibits leukocyte infiltration and splenocyte cytotoxicity against murine colon adenocarcinoma. <i>Oncology Reports</i> , 0, , .	2.6	3
136	Pentoxifylline promotes development of murine colon adenocarcinoma-derived metastatic tumors in liver. <i>Oncology Reports</i> , 2003, 10, 1805.	2.6	2
137	Differential influence of pentoxifylline on murine colon adenocarcinoma- and melanoma-derived metastatic tumor development in lungs. <i>Oncology Reports</i> , 2004, 11, 1121.	2.6	2
138	Genetic Modification of T Cells Improves the Effectiveness of Adoptive Tumor Immunotherapy. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2010, 58, 347-354.	2.3	2
139	Contribution of ER Stress to Immunogenic Cancer Cell Death. , 2012, , 413-428.		2
140	Can Developments in Tissue Optical Clearing Aid Super-Resolution Microscopy Imaging?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6730.	4.1	2
141	Improvement of anti-tumor activity of photodynamic therapy through inhibition of cytoprotective mechanism in tumor cells. , 2009, , .		1
142	Tissue clearingâ€based method for unobstructed threeâ€dimensional imaging of mouse penis with subcellular resolution. <i>Journal of Biophotonics</i> , 2020, 13, e202000072.	2.3	1
143	Antitumor effects of the combination therapy with TNF-Î± geneâ€modified tumor cells and interleukin 12 in a melanoma model in mice. , 0, .		1
144	Inhibitors Of Src Family and AKT Regulate The Activity Of CD20 Promoter. <i>Blood</i> , 2013, 122, 1838-1838.	1.4	1

#	ARTICLE	IF	CITATIONS
145	Peroxiredoxins-1 and 2 Affect Proliferation and Survival of Lymphoma Cells. <i>Blood</i> , 2014, 124, 1693-1693.	1.4	1
146	Lovastatin potentiates antitumor effects of saquinavir against human lymphoma cells. <i>Oncology Reports</i> , 0, , .	2.6	1
147	IL-12 or IL-15, unlike IL-2, does not interact with histamine in augmenting cytotoxicity of splenocytes against melanoma cells and YAC-1 cells. <i>Oncology Reports</i> , 0, , .	2.6	1
148	HDAC6 Inhibition Increases CD20 Level and Improves The Efficacy Of Anti-CD20 Monoclonal Antibodies. <i>Blood</i> , 2013, 122, 4406-4406.	1.4	1
149	Evaluation of the Antitumor Immune Response Following Photofrin-Based PDT in Combination with the Epigenetic Agent 5-Aza-2-Deoxycytidine. <i>Methods in Molecular Biology</i> , 2022, 2451, 559-567.	0.9	1
150	Potentiated antitumor effects of butyrate and actinomycin D in melanoma model in mice. <i>Oncology Reports</i> , 2002, 9, 199.	2.6	0
151	Determination of Aldehyde Dehydrogenase (ALDH) Isozymes in Human Cancer Samples - Comparison of Kinetic and Immunochemical Assays. <i>Molecules</i> , 2002, 7, 896-901.	3.8	0
152	Proteasome inhibitors in the treatment of cancer. <i>Drug Discovery Today</i> , 2003, 8, 575.	6.4	0
153	Potentiated antitumor effects of a combination therapy with a farnesyltransferase inhibitor L-744,832 and butyrate in vitro. <i>Oncology Reports</i> , 0, , .	2.6	0
154	Sorafenib Affects Membrane Complement Inhibitors and Improves Antitumor Activity of Rituximab,. <i>Blood</i> , 2011, 118, 3723-3723.	1.4	0
155	Preyl Transferases Are Involved in the Regulation of CD20 Levels and Influence Anti-CD20 Monoclonal Antibody-Mediated Activation of Complement-Dependent Cytotoxicity,. <i>Blood</i> , 2011, 118, 3722-3722.	1.4	0
156	Src Family Tyrosine Kinases Are Involved in the Transcriptional Regulation of CD20 Levels. <i>Blood</i> , 2011, 118, 1661-1661.	1.4	0
157	Inhibitors Of B-Cell Receptor Molecules Affect Surface CD20 and Impair Antitumor Activity Of Anti-CD20 Monoclonal Antibodies. <i>Blood</i> , 2013, 122, 4217-4217.	1.4	0
158	SK053 An Inhibitor Of Enzymes Involved In Allosteric Disulfide Bonds Formation Induces Differentiation Of Human AML Cells. <i>Blood</i> , 2013, 122, 4215-4215.	1.4	0
159	HDAC Inhibitors As Potential New Agents Improving the Efficacy of Monoclonal Antibodies. <i>Blood</i> , 2014, 124, 3641-3641.	1.4	0
160	GRP78-targeting Sensitizes Cancer Cells to Cytotoxic Effects of Photodynamic Therapy. Resistance To Targeted Anti-cancer Therapeutics, 2015, , 149-161.	0.1	0
161	SK053, an Inhibitor of Enzymes Involved in Allosteric Disulfide Bonds Formation, Targets Expression of Histone Genes and Induces Differentiation of Human AML Cell. <i>Blood</i> , 2014, 124, 3503-3503.	1.4	0
162	MEK1 Inhibitor Selumetinib Sensitizes Precursor B-Cell Acute Lymphoblastic Leukemia Cells (B-ALL) to Dexamethasone through Modulation of mTOR Activity and Stimulation of Autophagy. <i>Blood</i> , 2015, 126, 4917-4917.	1.4	0

#	ARTICLE	IF	CITATIONS
163	Inhibition of PIM Kinases in Diffuse Large B-Cell Lymphoma Cells Targets MYC-Dependent Transcriptional Program, Increases CD20 Expression and Augments the Efficacy of Anti-CD20 Antibodies. <i>Blood</i> , 2020, 136, 33-34.	1.4	0
164	Pharmacological Induction of NOXA Sensitizes High-Risk B Cell Acute Lymphoblastic Leukemia Cells to Venetoclax. <i>Blood</i> , 2020, 136, 17-18.	1.4	0